The first targeted therapy to treat pain crises in people with sickle cell disease, which was recently approved by the FDA, presents a “welcome” new option that payers likely will embrace, a PBM head tells AIS Health. While the drug’s manufacturer cites “positive” early discussions with payers on it, some experts note the lifetime treatment — via a monthly intravenous infusion — is costly: around $100,000 annually.
Most Recent
Though Care Utilization Rebounds, Insurers Still Face Uncertainty in 2021
Abstract, Health PlansDatapoint: Urovant Prepares for March Gemtesa Launch
Datapoint, Drug BenefitsUnitedHealth: Health Care Spending Returned to Normal in 4Q
Abstract, Health PlansDatapoint: Fallon Health Brings Drug Pricing Tool to Medicare Advantage Members
Datapoint, Health PlansCMS Boosts Medicare Advantage Rates, Cites COVID Costs
Abstract, Medicare and Medicaid